Newsfeeds Archive - Spark Newswire

3 minute read

Ligand Pharmaceuticals Announces Launch Of Pelthos Therapeutics To Accelerate Commercialization Of ZELSUVMI, Scott Plesha Named CEO

April 3, 9:05 AM

Pharmaceutical executive Scott Plesha named CEOLead product ZELSUVMI expected to be commercially available in late 2024Ligand Pharmaceuticals (NASDAQ:LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a

LGND

2 minute read

Ligand Holds Investor And Analyst Day; Provides Update On Portfolio Progress And Recent Transactions; Introduces 2024 Guidance; Sees FY24 EPS $4.25-$4.75 Vs $4.17 Est.; Revenue $130M-$142M Vs $138.6M Est.

By Benzinga Newsdesk

December 12, 1:06 PM

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) hosted anInvestor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior management team provided an overview of the

LGND

3 minute read

Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of QTORIN Rapamycin For Microcystic Lymphatic Malformations And Additional High Unmet Need Clinical Indications; Palvella Received $5M Payme…

By Benzinga Newsdesk

December 1, 9:23 AM

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with

LGND

1 minute read

Merck Highlights Data On New Vaccine, Compares ‘Tolerability And Safety’ To Pfizer’s

By Vandana Singh

November 28, 1:03 PM

Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent

LGND

1 minute read

Earnings

Ligand Pharmaceuticals: Q3 Earnings Insights

By Benzinga Insights

November 8, 5:10 PM

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM. Here’s what…

LGND

24 minute read

Earnings

Earnings Scheduled For November 8, 2023

By Benzinga Insights

November 8, 5:21 AM

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

AADI

4 minute read

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma

By Benzinga Newsdesk

September 22, 9:01 AM

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals plc (NASDAQ:JAZZ), ("Jazz") has been granted marketing authorization by the European Commission (EC) for Enrylaze®

JAZZ

1 minute read

Ligand’s Partner Travere Therapeutics Announces Confirmatory Data From The Phase 3 Protect Study Of Filspari Demonstrating Long-Term Kidney Function Preservation In IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint Versus Active Control

By Benzinga Newsdesk

September 21, 9:21 AM

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc.

LGND

2 minute read

Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary

By Vandana Singh

September 19, 1:15 PM

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio Inc.

LGND